Tao Liu, Zhiyong Weng, Xiaowu Dong and Yongzhou Hu Pages 1277 - 1292 ( 16 )
CCR5 (C-C chemokine receptor type 5) is a chemokine receptor that has been identified as a major HIV coreceptor in viral entry and therefore is a highly validated target for the development of new anti-HIV drugs. Here, we discuss the insights gained so far relevant to the development of small-molecule CCR5 inhibitors for the treatment of HIV, and highlight small-molecule CCR5 inhibitors that are currently under preclinical and clinical trials.
HIV, Entry, Co-receptor, CCR5, Small-molecule inhibitor, Maraviroc
ZJU-ENS Joint Laboratory of Medicinal Chemistry, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.